NVAX Q1 2024 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$94M+1560.1% YoY

Gross Profit

$45M48.0% margin

Operating Income

-$139M-147.8% margin

Net Income

-$148M-157.2% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

-67.8%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$91M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$2.2B

Stockholders' Equity

-$867M

Cash & Equivalents

$481M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$94M	-$6M	+1560.1%
Gross Profit	$45M	-$41M	+211.2%
Operating Income	-$139M	-$313M	+55.6%
Net Income	-$148M	-$294M	+49.8%

Revenue Segments

Product

$82M88%

Royalties and Other

$12M12%

Geographic Segments

Europe

$90M110%

Rest of the World

-$2M-2%

North America

-$6M-8%